Evidence map›Paper›PMID 23963493›Full record

ReviewSeminars in immunopathology2013

Role of the aryl hydrocarbon receptor (AhR) in lung inflammation.

Celine A Beamer, David M Shepherd

Open access · greenAbstract readReview
In one paragraph

Review in Seminars in immunopathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. PARP7 protects the lung epithelial barrier from diverse environmental threats.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Celine A BeamerDepartment of Biomedical and Pharmaceutical Sciences, Center for Environmental Health Sciences, Skaggs School of Pharmacy and Allied Health Sciences, The University of Montana, 32 Campus Drive, Skaggs Building Room 284, Missoula, MT, 59812, USA.
David M Shepherd
Center for Environmental Health · US

Funding

THE ROLE OF PULMONARY SUBPOPULATIONS AND TH2 IMMUNITY IN BALB/C SILICOSIS MODELP20RR017670 · NCRR · UNIVERSITY OF MONTANA · PI WETZEL, SCOTT A · 2002 to 2011
$22.0M
Development of a novel platform for the delivery of AhR antagonists to DCs and T cellsR01ES013784 · NIEHS · UNIVERSITY OF MONTANA · PI SHEPHERD, DAVID M · 2006 to 2017
$4.0M
Fate and effects of nanomaterials in the gastrointestinal tractR15ES020993 · NIEHS · UNIVERSITY OF MONTANA · PI BEAMER, CELINE A · 2012 to 2012
$425k
NCRR NIH HHS P20 RR017670NIEHS NIH HHS R01 ES013784NIEHS NIH HHS R15 ES020993NIEHS NIH HHS R15 ES020993A
6 · The paper itself

Abstract

Millions of individuals worldwide are afflicted with acute and chronic respiratory diseases, causing temporary and permanent disabilities and even death. Oftentimes, these diseases occur as a result of altered immune responses. The aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor, acts as a regulator of mucosal barrier function and may influence immune responsiveness in the lungs through changes in gene expression, cell-cell adhesion, mucin production, and cytokine expression. This review updates the basic immunobiology of the AhR signaling pathway with regards to inflammatory lung diseases such as asthma, chronic obstructive pulmonary disease, and silicosis following data in rodent models and humans. Finally, we address the therapeutic potential of targeting the AhR in regulating inflammation during acute and chronic respiratory diseases.

Indexed as

AnimalsAsthmaHumansInflammationLung DiseasesPulmonary Disease, Chronic ObstructiveReceptors, Aryl HydrocarbonSilicosisReceptors, Aryl Hydrocarbon

Identifiers

PMID23963493
PMCPMC3821999
OpenAlexW2092815970

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.